555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

Abstract

The integrins comprise a multifaceted family of membrane-associated proteins that regulate cellular adhesion, motility and cytokinesis. Higher levels of integrin beta-6 predict poorer outcomes in patients with solid tumors such as colorectal, non-small cell lung, gastric and cervical cancers. The vedotin SGN-B6A is an investigational antibody–drug conjugate designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to integrin beta-6-expressing cells. Once internalized, intracellular MMAE disrupts microtubules causing cell cycle arrest and apoptosis.